Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc (BTAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
BioXcel Therapeutics to Present at ThinkEquity Conference GlobeNewswire - Tue Oct 29, 6:00AM CDT

BTAI : 0.6431 (-3.55%)
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder GlobeNewswire - Tue Oct 15, 6:00AM CDT

BTAI : 0.6431 (-3.55%)
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies FinancialNewsMedia - Wed Feb 14, 7:31AM CST

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

ONCY : 1.1800 (+2.61%)
ONC.TO : 1.66 (+4.40%)
EXEL : 34.12 (+2.77%)
PFE : 28.09 (-0.74%)
BTAI : 0.6431 (-3.55%)
BMY : 54.32 (-2.60%)
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies GlobeNewswire - Wed Feb 14, 7:30AM CST

ONCY : 1.1800 (+2.61%)
ONC.TO : 1.66 (+4.40%)
EXEL : 34.12 (+2.77%)
PFE : 28.09 (-0.74%)
BTAI : 0.6431 (-3.55%)
BMY : 54.32 (-2.60%)
Author
Unlocking AI investment opportunities in healthcare MarketBeat - Thu Nov 16, 2023

AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.

INTC : 23.20 (+7.81%)
NVDA : 135.40 (+1.99%)
RXRX : 6.40 (+1.27%)
RLAY : 5.84 (+3.64%)
EXAI : 4.90 (+0.82%)
RENB : 0.5368 (+0.88%)
BTAI : 0.6431 (-3.55%)
Why Shares of BioXcel Therapeutics Fell This Week Motley Fool - Thu Sep 28, 2023

The company's co-founder is leaving, and layoffs are coming.

BTAI : 0.6431 (-3.55%)
Important September 5, 2023 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. Investors of Securities Fraud Class Action Lawsuit PR Newswire - Sun Sep 3, 2023

/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in...

BTAI : 0.6431 (-3.55%)
BTAI DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI PR Newswire - Sat Sep 2, 2023

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between...

BTAI : 0.6431 (-3.55%)
BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options PR Newswire - Sat Sep 2, 2023

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioXcel Therapeutics, Inc. ("BioXcel"...

BTAI : 0.6431 (-3.55%)
SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc.(BTAI) Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire - Thu Aug 31, 2023

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities...

BTAI : 0.6431 (-3.55%)

Barchart Exclusives

McDonald's Hikes Its Dividend 6% - MCD Stock's 2.40% Yield Attracts Value Buyers Barchart - 45 minutes ago
McDonald's Corp. reported lower global comp sales and its recent E. coli outbreak pushed MCD stock down. These could be temporary issues. The good news is that it hiked the dividend by 6%, and MCD looks attractive historically. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot